Efficacy of Fluticasone and Salmeterol Dry Powder in Treating Patients with Bronchial Asthma and Its Effect on Inflammatory Factors and Pulmonary Function

Objective. To evaluate the efficacy of fluticasone and salmeterol dry powder in treating patients with bronchial asthma and its effects on inflammatory factors and pulmonary function. Methods. One hundred patients with bronchial asthma, admitted to our hospital between April 2019 and June 2020, were enrolled and assigned into two groups using the random number table method. The observation group (n = 50) received budesonide powder, and the experimental group received fluticasone and salmeterol dry powder. The two groups were compared with regard to clinical efficacy, inflammatory factors, pulmonary function, and adverse reactions. Results. In the experimental group, the total effective rate of treatment was significantly higher than that in the observation group ( P < 0.05 ); after treatment, the levels of inflammatory factors in the experimental group were lower than those in the observation group ( P < 0.05 ); after treatment, lung function in the experimental group was significantly higher than that in the observation group ( P < 0.05 ); the incidence of adverse reactions in the experimental group was significantly lower than that in the observation group ( P < 0.05 ). Conclusion. Salmeterol and fluticasone powder has shown impressive clinical benefits in the treatment of bronchial asthma patients. It might be a viable approach to reduce inflammatory factors and improve pulmonary function. Moreover, its good clinical safety profile makes it a promising treatment that ought to be promoted and used widely.